The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. These agents have become fully integrated into current treatment practices for unresectable locally advanced or metastatic bladder cancer. Biomarker-driven treatments are becoming increasingly attractive, as highlighted by Balversa’s FDA approval in April 2019. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for both muscle-invasive and non-muscle-invasive bladder cancer within the forecast period.

Questions Answered

  • What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer populations, and how will drug-treatment rates change over time?
  • How is bladder cancer currently treated, and what are the (dis)advantages of existing drugs? What is the expected market impact of recent approvals?
  • Which of the emerging therapies seem most promising, and what sales/uptake could they secure in the bladder cancer market?
  • What are the drivers and constraints in the bladder cancer market, and how will the market evolve over the ten-year forecast period?

Geographies: United States, EU5, Japan.

Primary Research: 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.

Forecast: Ten-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2028, segmented by brands/generics and epidemiological subpopulations.

Emerging Therapies: Phase III/PR: 6 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Bladder Cancer | Current Treatment | Detailed, Expanded Analysis: Physician Insights (US)

The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s...

View Details

Bladder Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Bladder Cancer | Landscape & Forecast | Disease Landscape & Forecast

The 2016/17 FDA ap...

View Details

Bladder Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU5)

The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape...

View Details